Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

BIO Digital sessions now available on demand

Last week at BIO Digital, Dr. Michelle McMurry-Heath, BIO’s President & CEO, moderated the panel “Leading Through Crisis: Speaking Up and Out on Equity, Diversity,...

| By Kelley Gipson

Azitra moves to Branford to accommodate growth

Azitra has opened its new 12,000 square foot laboratory and office complex in Branford, CT. Previously operating out of three small labs located at the...

| By Kelley Gipson

CT medical marijuana program to treat chronic pain

The Connecticut Legislature’s Regulations Review Committee has approved two new conditions to allow patients with chronic pain and an inherited disorder that affects the body’s...

| By Kelley Gipson

Dementia gene raises risk of severe COVID-19

Having a faulty gene linked to dementia doubles the risk of developing severe COVID-19, according to a large-scale study. Researchers at the University of Exeter...

| By Kelley Gipson

Genetic-based precision medicine holds promise

A type of personalized care known as precision medicine, and its subset, genomic medicine, is now the standard of care in Connecticut’s Hartford HealthCare Cancer Institute, UConn...

| By Kelley Gipson

BioCT stands with BLM

“Black Lives Matter and BioCT is committed to addressing racism through members’ employment practices, their development of therapeutics to benefit all patients and our support of...

| By Kelley Gipson

Pfizer establishes new innovation program

Pfizer is establishing the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help provide funding and...

| By Kelley Gipson

CT bioscience a leader in fight against COVID-19

As Connecticut continues to face one of the world’s deadliest COVID-19 outbreaks, the state’s bioscience industry has aggressively turned its focus to developing new breakthrough...

| By Kelley Gipson

LambdaVision secures funding re artificial retina

LambdaVision has been selected by NASA for a Small Business Innovation Research (SBIR) Phase II award, worth $750,000 over two years. With the continued support...

| By Kelley Gipson

InveniAI in strategic partnership with TB Alliance

InveniAI® LLC has formed a strategic partnership with TB Alliance, a non-profit organization dedicated to the discovery, development, and delivery of better, faster-acting and affordable...